$8 million funding will go towards development and scaling of Sensely’s virtual nurse app.
But trial in patients in early stage of the disease continues.
Body unconvinced by clinical data for Venclyxto .
UK biotech has stake in two potentially lucrative drugs thanks to hybrid business model
Care standards could be compromised in underfunded NHS, warns QC.
But GSK hit back with plans for two-drug regimen.
Company says it will listen to concerns of patient advocates
HeartFlow could save NHS England a minimum of around £9.1 million by 2022.
Oral treatment could take the lead among next generation RA drugs